Effectiveness and efficiency of platelet rich plasma in the treatment of diabetic ulcers

Curr Pharm Biotechnol. 2015;16(7):630-4. doi: 10.2174/138920101607150427111926.

Abstract

"There is a growing body of evidence suggesting that wound healing in chronic diabetic foot ulcers is growth factor dependent, and that the therapeutic delivery of these growth factors to wounds topically, has the potential ability to accelerate wound healing in conjunction with conventional wound care". There is, however, confusion about the utility of platelet rich plasma because the studies that have evaluated them use a wide range of products (different platelet and leukocyte concentrations, different techniques and frequencies of application, very heterogeneous simple, and different endpoints) making almost impossible to compare data and draw conclusions. In this study, we have analyzed the different platelet rich plasma products from a new perspective: cost-efficiency. According to our data, we observe that platelet rich plasma is a cost-effective option that allows faster healing of ulcers, and that should be taken into account in patients with long evolution ulcers.

Publication types

  • Review

MeSH terms

  • Animals
  • Cost-Benefit Analysis* / methods
  • Diabetic Foot / diagnosis
  • Diabetic Foot / economics*
  • Diabetic Foot / therapy*
  • Humans
  • Platelet-Rich Plasma*
  • Randomized Controlled Trials as Topic / economics
  • Randomized Controlled Trials as Topic / methods
  • Treatment Outcome
  • Wound Healing / physiology